Signal transduction targets in androgen-independent prostate cancer

被引:22
作者
Zhou, J [1 ]
Scholes, J [1 ]
Hsieh, JT [1 ]
机构
[1] Univ Texas, SW Med Ctr, Dept Urol, Dallas, TX USA
关键词
prostate cancer; androgen-independent prostate cancer; signal transduction; growth factor; tumor suppressor;
D O I
10.1023/A:1015504015302
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Prostate cancer (PCa) first manifests as an androgen-dependent disease. Thus, androgen-deprivation therapy is a standard regimen for patients with metastatic PCa. Despite the initial success of androgen-deprivation therapy, PCa inevitably progresses from being androgen dependent (AD) to androgen independent (AI), and this marks the poor prognosis of this disease. Relapse of AIPCa becomes life threatening and accounts for the majority of mortality of PCa patients. Currently, no effective therapy is available for controlling AIPCa. Therefore, the challenge in providing a new intervention is to understand the fundamental changes that occur in AIPCa. Increasing evidence indicates that, under androgen-deprived milieu, several signal networks elicited by peptide growth factors dictate the AI phenotype of PCa. This review covers the latest studies investigating the potential involvement of autocrine growth factors in cell proliferation, survival, metastasis, and the reciprocal interaction with the androgen receptor pathway. In addition, loss of the negative feedback mechanism of the signal cascade further amplifies the effect of growth factors, and thus contributes significantly to the onset of AIPCa. The understanding of the signal target(s) in AIPCa should provide the new markers for prognosis and a new strategy for prevention and therapy.
引用
收藏
页码:351 / 362
页数:12
相关论文
共 132 条
[71]  
McConkey DJ, 1996, CANCER RES, V56, P5594
[72]  
MCKEEHAN WL, 1984, CANCER RES, V44, P1998
[73]   DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer [J].
Mok, SC ;
Chan, WY ;
Wong, KK ;
Cheung, KK ;
Lau, CC ;
Ng, SW ;
Baldini, A ;
Colitti, CV ;
Rock, CO ;
Berkowitz, RS .
ONCOGENE, 1998, 16 (18) :2381-2387
[74]   The MMAC1 tumor suppressor phosphatase inhibits phospholipase C and integrin-linked kinase-activity [J].
Morimoto, AM ;
Tomlinson, MG ;
Nakatani, K ;
Bolen, JB ;
Roth, RA ;
Herbst, R .
ONCOGENE, 2000, 19 (02) :200-209
[75]   The gene encoding the mitogen-responsive phosphoprotein Dab2 is differentially regulated by GATA-6 and GATA-4 in the visceral endoderm [J].
Morrisey, EE ;
Musco, S ;
Chen, MYZ ;
Lu, MM ;
Leiden, JM ;
Parmacek, MS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (26) :19949-19954
[76]   INFREQUENT RAS ONCOGENE MUTATIONS IN HUMAN PROSTATE-CANCER [J].
MOUL, JW ;
FRIEDRICHS, PA ;
LANCE, RS ;
THEUNE, SM ;
CHANG, EH .
PROSTATE, 1992, 20 (04) :327-338
[77]  
NAKAMOTO T, 1992, CANCER RES, V52, P571
[78]  
NAKAZAWA H, 1992, ONCOGENE, V7, P2295
[79]   Elevated Akt activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis [J].
Nesterov, A ;
Lu, XJ ;
Johnson, M ;
Miller, GJ ;
Ivashchenko, Y ;
Kraft, AS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (14) :10767-10774
[80]  
NOBLE RL, 1977, CANCER RES, V37, P1929